Company profile
Arcutis Biotherapeutics, Inc.
NASDAQ: ARQT · Healthcare · Biotechnology
#232 of 1,417 Healthcare companies by revenuetop-quartile growth
EA Score
66BFH 74DQ 53GM 65SS 67
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, market scale · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$415.6M
Rev growth YoY (TTM)
+95.3%
Net income (FY)
-$16.1M
Employees
354
as of 2026-08-08
Market cap
$3.2B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$372.1M$372.1M2025
Net income-$16.1M-$16.1M2025
Operating income-$12.2M-$12.2M2025
Total assets$433.0M$433.0M2025
Liabilities$243.5M$243.5M2025
Equity$189.5M$189.5M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2023
By product
Other Revenue51%
Product49%
By geography
Not disclosed.
The read
What is Arcutis Biotherapeutics, Inc.’s revenue?
Arcutis Biotherapeutics, Inc. booked $372.1M in FY2025 revenue, growing 123% year over year — faster than most Healthcare companies we track, at a -4.3% net margin.
Peers · Healthcare
Sonida Senior Living, Inc.64CCareDx, Inc78B+Twist Bioscience Corporation70BAtea Pharmaceuticals, Inc.47DMannKind Corporation69BTruBridge, Inc.75B+Neighbors
Los Angeles →Key facts
CEOTodd Franklin Watanabe
SectorHealthcare
IndustryBiotechnology
HeadquartersWestlake Village, CA
ExchangeNASDAQ: ARQT
Employees354
IPO date2020-01-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.